Literature DB >> 21532337

Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors.

Snehal Dabir1, Amy Kluge, Mohammad A Aziz, Janet A Houghton, Afshin Dowlati.   

Abstract

Protein Inhibitor of Activated Signal Transducer and Activators of Transcription 3 (PIAS3) is a molecule that regulates STAT3 and has antiproliferative properties. Glioblastoma and squamous cell lung cancer lack PIAS3 expression. To test the hypothesis that PIAS3 transcriptional effects are STAT3-independent, we developed models for STAT3 knockdown and PIAS3 over-expression. PIAS3 expression results in a distinct transcriptional profile that does not occur with STAT3 knockdown. We identify novel transcription factor binding partners for PIAS3 including ETS, EGR1, NR1I2, and GATA1. PIAS3 binds to these factors and regulates their transcriptional effects resulting in alterations in canonical pathways including Wnt/β-catenin signaling and functions such as cell death and proliferation. A model is proposed by which PIAS3 effects EGR1 regulated pathways.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21532337      PMCID: PMC3154286          DOI: 10.4161/cbt.12.2.15732

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  32 in total

Review 1.  Stats: transcriptional control and biological impact.

Authors:  David E Levy; J E Darnell
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

2.  Protein inhibitor of activated STAT3 expression in lung cancer.

Authors:  Amy Kluge; Snehal Dabir; Ilse Vlassenbroeck; Rosana Eisenberg; Afshin Dowlati
Journal:  Mol Oncol       Date:  2011-03-30       Impact factor: 6.603

3.  The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251.

Authors:  C Liu; J Yao; D Mercola; E Adamson
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

4.  Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers.

Authors:  J Fujimoto; I Aoki; H Toyoki; S Khatun; T Tamaya
Journal:  Ann Oncol       Date:  2002-10       Impact factor: 32.976

Review 5.  Structural insights into the promiscuity and function of the human pregnane X receptor.

Authors:  Ryan E Watkins; Schroeder M Noble; Matthew R Redinbo
Journal:  Curr Opin Drug Discov Devel       Date:  2002-01

Review 6.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

Authors:  Ralf Buettner; Linda B Mora; Richard Jove
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

7.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Authors:  Liat Rainis; Dan Bercovich; Sabine Strehl; Andrea Teigler-Schlegel; Batia Stark; Jan Trka; Ninette Amariglio; Andrea Biondi; Inna Muler; Gideon Rechavi; Helena Kempski; Oskar A Haas; Shai Izraeli
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

8.  Transforming growth factor-beta-mediated signaling via the p38 MAP kinase pathway activates Smad-dependent transcription through SUMO-1 modification of Smad4.

Authors:  Takayuki Ohshima; Kunitada Shimotohno
Journal:  J Biol Chem       Date:  2003-09-26       Impact factor: 5.157

9.  Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.

Authors:  Lanxi Song; James Turkson; James G Karras; Richard Jove; Eric B Haura
Journal:  Oncogene       Date:  2003-07-03       Impact factor: 9.867

10.  A transcriptional response to Wnt protein in human embryonic carcinoma cells.

Authors:  Jennifer Willert; Mirjam Epping; Jonathan R Pollack; Patrick O Brown; Roel Nusse
Journal:  BMC Dev Biol       Date:  2002-07-02       Impact factor: 1.978

View more
  4 in total

1.  Proximal microdeletions and microduplications of 1q21.1 contribute to variable abnormal phenotypes.

Authors:  Jill A Rosenfeld; Ryan N Traylor; G Bradley Schaefer; Elizabeth W McPherson; Blake C Ballif; Eva Klopocki; Stefan Mundlos; Lisa G Shaffer; Arthur S Aylsworth
Journal:  Eur J Hum Genet       Date:  2012-02-08       Impact factor: 4.246

2.  Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation.

Authors:  Gaurav Kumar; S Nahum Goldberg; Svetlana Gourevitch; Tatyana Levchenko; Vladimir Torchilin; Eithan Galun; Muneeb Ahmed
Journal:  Radiology       Date:  2017-09-06       Impact factor: 11.105

3.  STAT3 and its phosphorylation are involved in HIV-1 Tat-induced transactivation of glial fibrillary acidic protein.

Authors:  Yan Fan; Khalid Amine Timani; Johnny J He
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

4.  Expression of STAT5, COX-2 and PIAS3 in correlation with NSCLC histhopathological features.

Authors:  Dorota Pastuszak-Lewandoska; Daria Domańska; Karolina H Czarnecka; Jacek Kordiak; Monika Migdalska-Sęk; Ewa Nawrot; Justyna Kiszałkiewicz; Adam Antczak; Paweł Górski; Ewa Brzeziańska
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.